Contact Us EN / 中
  • Company
  • People
  • Pipeline
    • Our Pipeline
    • Izokibep (IMG-020)
  • Partnering
    • In-Licensing
  • News & Events
  • careers
  • CONTACT US
    EN / 中
Borderless Innovation
guided byGlobal Intelligence

About Inmagene

Learn more

Our pipeline

Inmagene has a robust and growing pipeline of nearly 20 drug candidates, focused on treating immunological diseases.
Learn more

Clinical Trials

Inmagene is enrolling patients for a Phase 2 clinical study of Izokibep for Ankylosing Spondylitis in the US.
Learn more

Partnering

Inmagene has formed strategic partnerships with Affibody AB, HUTCHMED (Nasdaq/AIM: HCM) and Kissei to develop and commercialize highly innovative drug candidates.

Inmagene has several assets with strong differentiations available for Partnering.

Learn more
News and Events
View all news
Copyright © . Inmagene All rights reserved. 沪ICP备2021011492号-1